Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMAP), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (NASDAQ: XOMAP) operates at the intersection of biotechnology and strategic finance, specializing in non-dilutive funding models for therapeutic development. This page serves as the definitive source for XOMA-related news, offering investors and industry professionals timely updates on licensing agreements, portfolio milestones, and financial developments.
Access curated press releases and analysis covering royalty acquisition deals, therapeutic program advancements, and financial performance updates. Our repository includes critical announcements about antibody therapeutics licensing, partnership expansions, and regulatory progress across XOMA's diversified portfolio.
Key content categories include earnings reports, strategic collaborations in oncology and rare diseases, and updates on milestone payments from commercial-stage therapies. Track the company's unique position in biotech finance through verified updates about its royalty aggregation model and portfolio risk management strategies.
Bookmark this page for streamlined access to XOMA's evolving role in enabling drug development through innovative capital solutions. Check regularly for authoritative updates on how the company navigates therapeutic licensing economics while maintaining a balanced asset portfolio.
XOMA , a biotech royalty aggregator listed on NASDAQ under the symbol 'XOMA', announced its participation in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference. The event will take place at NASDAQ in New York on May 20, 2024.
CEO Owen Hughes and CIO Brad Sitko will represent XOMA in a fireside chat scheduled for 11:00 AM ET. The presentation can be accessed online via a provided link, and replays will be available on XOMA's investor relations website for 90 days post-event.
XOMA reported its first quarter 2024 financial results, earning a $9 million milestone with the FDA approval of OJEMDA™, gaining $9.5 million from Kinnate acquisition, expanding its portfolio, and initiating a $50 million stock repurchase program. The company also reported $1.5 million in total revenues for Q1 2024.
XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMAP)?
